Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 176 to 200 of 797

TitleReference numberPublishedLast updated
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatmentsTA852
Esketamine nasal spray for treatment-resistant depressionTA854
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)TA845
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)TA846
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)TA847
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)TA844
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)TA843
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA841
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)TA842
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal)TA839
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)TA840
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)TA838
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanomaTA837
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA836
Pembrolizumab for adjuvant treatment of renal cell carcinomaTA830
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroidsTA832
Zanubrutinib for treating Waldenstrom's macroglobulinaemiaTA833
Fostamatinib for treating refractory chronic immune thrombocytopeniaTA835
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal)TA834
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapyTA827
Ozanimod for treating moderately to severely active ulcerative colitisTA828
Upadacitinib for treating active ankylosing spondylitisTA829
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA823

Results per page

  1. 10
  2. 25
  3. 50
  4. All